Head-to-head evidence
Icodextrin (peritoneal ultrafiltration) vs PolyCore
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Peritoneal ultrafiltration · full Heart Failure pipeline
Icodextrin (peritoneal ultrafiltration) · Extraneal
Marketed by Vantive Health
NCT00368641 · Phase 2 · terminated
A randomized, open-label study of peritoneal ultrafiltration with icodextrin versus standard therapy in 12 participants with heart failure, terminated before any participant completed the treatment period. The posted primary, all-cause hospitalization rate, has no statistical analysis and rests on a handful of participants, so the result cannot be determined.
PolyCore
Developed by Iperboreal Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT03994874 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icodextrin (peritoneal ultrafiltration)'s landscape · PolyCore's landscape